

IDS - 07/21/2019 **ELECTRONIC INFORMATION DISCLOSURE STATEMENT**

Electronic Version v18

Stylesheet Version v18.0

Title of Invention	Methods of Treating Diseases Responsive to Induction of Apoptosis and Screening Assays
-----------------------	---

Application Number : 10/826909



Confirmation Number: 1721

First Named Applicant: Shailaja Kasibhatla

Attorney Docket Number: 1735.0840002

Art Unit: 1614

Examiner: To be determined

Search string: (4980281 or 5648469 or 5691157 or 5702890 or 5827516 or 6132981 or 6171807 or 6197294 or 6333031 or 4434156 or 4545985 or 4956453 or 5141736 or 5208021 or 5352447 or 5667781 or 5728383 or 5762932 or 5776458 or 5792458 or 5798097 or 6265229 or 6290929 or 6294330 or 6384049 or 6399054 or 6245888 or 6462041 or 20010044457 or 20010047021 or 20020019415 or 20020025313 or 20020048550 or 20020103165 or 20020136732 or 20020160013 or 20020197262 or 20030021792 or 20030035808 or 20030040498 or 20030044408 or 20030072812).pn

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
BD	1	4980281	1990-12-25	Housey			
↓	2	5648469	1997-07-15	Trowbridge et al.			
↓	3	5691157	1997-11-25	Gong et al.			
↓	4	5702890	1997-12-30	Housman			
↓	5	5827516	1998-10-27	Urban et al.			
↓	6	6132981	2000-10-17	Gong et al.			
↓	7	6171807	2001-01-09	Novitsky et al.			
↓	8	6197294	2001-03-06	Tao et al.			
↓	9	6333031	2001-12-25	Olsson et al.			
↓	10	4434156	1984-02-28	Trowbridge			
↓	11	4545985	1985-10-08	Pastan et al.			
↓	12	4956453	1990-09-11	Bjorn et al.			
↓	13	5141736	1992-08-25	Iwasa et al.			
↓	14	5208021	1993-05-04	Johnson et al.			
↓	15	5352447	1994-10-04	Johnson et al.			
↓	16	5667781	1997-09-16	Trowbridge et al.			
↓	17	5728383	1998-03-17	Johnson et al.			
↓	18	5762932	1998-06-09	Kemp			

BD	19	5776458	1998-07-07	Angelucci et al.			
	20	5792458	1998-08-11	Johnson et al.			
	21	5798097	1998-08-25	McKenzie et al.			
	22	6265229	2001-07-24	Fodstad et al.	B1		
	23	6290929	2001-09-18	Camden	B1		
	24	6294330	2001-09-25	Michnick et al.	B1		
	25	6384049	2002-05-07	Camden	B1		
	26	6399054	2002-06-04	Casorati et al.	B1		
	27	6245888	2001-06-12	Staddon	B1		
↓	28	6462041	2002-10-08	Cai et al.	B1		


US Published Applications

Note: Applicant is not required to submit a paper copy of cited US Published Applications

init	Cite.No.	Pub. No.	Date	Applicant	Kind	Class	Subclass
BD	1	20010044457	2001-11-22	Camden	A1		
	2	20010047021	2001-11-29	Camden	A1		
	3	20020019415	2002-02-14	Camden	A1		
	4	20020025313	2002-02-28	Micklus et al.	A1		
	5	20020048550	2002-04-25	Vallera et al.	A1		
	6	20020103165	2002-08-01	Bot et al.	A1		
	7	20020136732	2002-09-26	Houston	A1		
	8	20020160013	2002-10-31	Olsson et al.	A1		
	9	20020197262	2002-12-26	Hasan et al.	A1		
	10	20030021792	2003-01-30	Roben et al.	A1		
	11	20030035808	2003-02-20	Srivastava	A1		
	12	20030040498	2003-02-27	Ansardi et al.	A1		
	13	20030044408	2003-03-06	Levy et al.	A1		
↓	14	20030072812	2003-04-17	Sirbasku	A1		

Signature

Examiner Name	Date
/Brad Duffv/	12/21/2006



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project 07-005, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/826,909
		Filing Date	April 19, 2004
		First Named Inventor	Kasibhatla, S.
		Art Unit	1614
		Examiner Name	To be determined
Sheet	1	of	2
		Attorney Docket Number	1735.0840002/RWE/ALS

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
BD	NPL1	Abstract of Bridge, J.A., <i>et al.</i> , "Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor," <i>Am. J. Pathol.</i> 159:411-415, The American Society for Investigative Pathology (2001)	
	NPL2	Abstract of Geminard, C., <i>et al.</i> , "Reticulocyte maturation: mitoptosis and exosome realease," <i>Biocell</i> 26:205-215, Instituto de Histologia y Embriologia (August 2002)	
	NPL3	Abstract of Hayashida-Hibino, S., <i>et al.</i> , "The effect of TGF-beta1 on differential gene expression profiles in human corneal epithelium studied by cDNA expression array," <i>Invest. Ophthalmol. Vis. Sci.</i> 42:1691-1697, The Association for Research in Vision and Ophthalmology (2001)	
	NPL4	Abstract of Kalivendi, S.V., <i>et al.</i> , "1-Methyl-4-phenylpyridinium (MPP+)-induced apoptosis and mitochondrial oxidant generation: role of transferrin-receptor-dependent iron and hydrogen peroxide," <i>Biochem. J.</i> 371:151-164, American Chemical Society (April 1, 2003)	
	NPL5	Abstract of Kedra, D., <i>et al.</i> , "Characterization of a second human clathrin heavy chain polypeptide gene (CLH-22) from chromosome 22q11," <i>Hum. Mol. Genet.</i> 5:625-631, Oxford University Press (1996)	
	NPL6	Abstract of Lesnikov, V., <i>et al.</i> , "Pro-apoptotic effects of transferrin and transferrin-derived glycans on hematopoietic cells and lymphocytes," <i>Exp. Hematol.</i> 29:477-489, International Society for Experimental Hematology and Elsevier Science, Inc. (2001)	
	NPL7	Abstract of Matsushima, T., <i>et al.</i> , "Receptor binding cancer antigen expressed on SiSo cells, a novel regulator of apoptosis of erythroid progenitor cells," <i>Blood</i> 98:313-321, American Society of Hematology (2001)	
	NPL8	Abstract of Prescott, JL and Tindall, D.J., "Clathrin gene expression is androgen regulated in the prostate," <i>Endocrinology</i> 139:2111-2119, The Endocrine Society (1998)	
	NPL9	Abstract of Pushkareva, M.Y., <i>et al.</i> , "Increased cell-surface receptor expression on U-937 cells induced by 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine," <i>Cancer Immunol. Immunother.</i> 48:569-578, Springer-Verlag GmbH (2000)	
	NPL10	Abstract of Szekeres, T., <i>et al.</i> , "Benzamide riboside, a recent inhibitor of inosine 5'-monophosphate dehydrogenase induces transferrin receptors in cancer cells," <i>Curr. Med. Chem.</i> 9:759-764, Bentham Science Publishers Ltd. (April 2002)	

Examiner Signature	/Brad Duffy/	Date Considered	12/21/2006
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/826,909		
		Filing Date	April 19, 2004		
		First Named Inventor	Kasibhatla, S.		
		Art Unit	1614		
		Examiner Name	To be determined		
Sheet	2	of	2	Attorney Docket Number	1735.0840002/RWE/ALS

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
BD	NPL11	Abstract of Tampo, Y., et al., "Oxidative stress-induced iron signaling is responsible for peroxide-dependent oxidation of dichlorodihydrofluorescein in endothelial cells: role of transferrin receptor-dependent iron uptake in apoptosis," <i>Circ. Res.</i> 92:56-63, Lippincott Williams & Wilkins (January 2003)	
	NPL12	Abstract of Thompson, K., et al., "Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress," <i>J. Neurosci. Res.</i> 71:46-63, John Wiley & Sons, Inc. (January 2003)	
	NPL13	Abstract of Touriol, C., et al., "Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like)," <i>Blood</i> 95:3204-3207, American Society of Hematology (2000)	
	NPL14	Abstract of Vaughan, A.T., et al., "The in vivo fate of a 211At labelled monoclonal antibody with known specificity in a murine system," <i>Int. J. Radiat. Oncol. Biol. Phys.</i> 8:1943-1946, Elsevier Inc.(1982)	
	NPL15	Abstract of Yen, C.F., et al., "Regulation of low-density lipoprotein receptors and assessment of their functional role in Burkitt's lymphoma cells," <i>Biochim. Biophys. Acta.</i> 1257:47-57, Elsevier B.V. (1995)	
	NPL16	Trowbridge, I.S., et al., "Structure-Function Analysis of the Human Transferrin Receptor: Effects of Anti-Receptor Monoclonal Antibodies on Tumor Growth," <i>Curr. Stud. Hematol. Blood Trans.</i> 58:139-147, Karger (1991)	

Examiner Signature	/Brad Duffy/	Date Considered	12/21/2006
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)</p>				<p>Complete if Known</p>	
<p>Application Number</p>				<p>10/826,909</p>	
<p>Filing Date</p>				<p>April 19, 2004</p>	
<p>First Named Inventor</p>				<p>Kasibhatla, S.</p>	
<p>Art Unit</p>				<p>1614</p>	
<p>Examiner Name</p>				<p>To be assigned</p>	
<p>Attorney Docket Number</p>				<p>1735.0840002/RWE/DJN</p>	

[illegible][illegible]


Examiner Signature	/Brad Duffy/	Date Considered	12/21/2006
-----------------------	--------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

576159



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/088 (07-05)

Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/826,909		
		Filing Date	April 19, 2004		
		First Named Inventor	Kasibhatla, S.		
		Art Unit	1614		
		Examiner Name	To be assigned		
Sheet	1	of	1	Attorney Docket Number	1735.0840002/RWE/DJN

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
BD	NPL17	ZHANG <i>et al.</i> , "Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay," <i>Bioorganic & Medicinal Chemistry</i> , 12:309-317, Elsevier Science, The Netherlands (January, 2004)	
↓	NPL18	KASIBHATLA <i>et al.</i> , "A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid," <i>Proc Natl Acad Sci U S A</i> , 102:12095-12100, The National Academy of Sciences, Washington D.C. (August, 2005)	
	NPL19	JESSEN <i>et al.</i> , "The discovery and mechanism of action of novel tumor-selective and apoptosis-inducing 3,5-diaryl-1,2,4-oxadiazole series using a chemical genetics approach," <i>Molecular Cancer Therapeutics</i> , 4:761-771, American Association for Cancer Research, Inc., Philadelphia, PA (May, 2005)	
	NPL20	International Search Report and Written Opinion, International Application No. PCT/US04/11915, mailed June 27, 2006	
	NPL21		
	NPL22		
	NPL23		
	NPL24		
	NPL25		
	NPL26		

Examiner Signature	/Brad Duffy/	Date Considered	12/21/2006
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

576142